11732 Federal Register / Vol. 87, No. 41 / Wednesday, March 2, 2022 / Notices 

other activities for these drug codes are 

authorized for this registration. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–04324 Filed 3–1–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–968] 

Importer of Controlled Substances 

Application: Janssen Pharmaceuticals, 

Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Janssen Pharmaceuticals Inc., 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to Supplementary 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before April 1, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 1, 2022. 

ADDRESSES: The DEA requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on December 10, 2021, 

Janssen Pharmaceuticals Inc, 1440 

Olympic Drive, Buildings 1–5 and 7–14, 

Athens, Georgia 30601–1645, applied to 

be registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Thebaine ................................... 9333 II 

Poppy Straw Concentrate ......... 9670 II 

Tapentadol ................................ 9780 II 

The company plans to import 

intermediates classified under 

Tapentadol (9780) and Thebaine (9333) 

for further manufacturing to the 

controlled substances tapentadol and 

buprenorpine, respectively, prior to 

distribution to customers. The company 

plans to import Poppy Straw 

Concentrate (9670) to bulk manufacture 

other controlled substances. No other 

activity for this drug code is authorized 

for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–04321 Filed 3–1–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–959] 

Importer of Controlled Substances 

Application: Medi-Physics Inc. dba GE 

Healthcare 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Medi-Physics Inc. dba GE 

Healthcare has applied to be registered 

as an importer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before April 1, 2022. Such persons 

may also file a written request for a 

hearing on the application on or before 

April 1, 2022. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on December 16, 2021, 

Medi-Physics Inc. dba GE Healthcare, 

3350 North Ridge Avenue, Arlington 

Heights, Illinois 60004–1412, applied to 

be registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Cocaine ..................................... 9041 II 

Ecgonine ................................... 9180 II 

The company plans to import 

derivatives of the listed controlled 

substances to be used for the 

manufacture of a diagnostic product and 

reference standards. No other activity 

for these drug codes is authorized for 

this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew J. Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2022–04371 Filed 3–1–22; 8:45 am] 

BILLING CODE P 


lotter on DSK11XQN23PROD with NOTICES1

I I